TRT statistics 2026: prescriptions, costs and who uses testosterone

of male patients had an active testosterone prescription in 2025¹

Epic Research analysis of 109 million men aged 18 and older with at least one health care encounter between January 2012 and June 2026.

of male patients had an active testosterone prescription in the first half of 2026¹

Partial-year figure; the share fell from a peak of 0.83% in 2013 to a low of 0.64% in 2021 before rising again.

people filled a testosterone prescription in 2022 in the states studied, up from 1,216,982 in 2018²

Unique patients in state prescription drug monitoring program data, all sexes. The authors report a 27% relative increase in people treated.

of the population in the states studied was treated with testosterone in 2022, up from 0.76% in 2018²

The authors describe this as a 30% increase in prevalence.

patients received a prescription for a testosterone product in 2013, up from 1.3 million in 2009³

FDA figures from its March 2015 safety communication.

of men receiving testosterone prescriptions through retail pharmacies were 40 to 64 years old³

FDA states the share as approximately 70 percent, in its 2015 communication.

of commercially insured US men aged 40 and older used androgens in 2011, up from 0.81% in 2001⁴

Claims from 10,739,815 men in the Clinformatics DataMart database. The authors describe the rise as more than 3-fold.

of men aged 30 and older used testosterone at the 2013 peak, up from 0.52% in 2002⁵

Commercial claims data.

of men aged 30 and older used testosterone in 2016, after prescribing fell from the 2013 peak⁵

relative decrease in new testosterone users between 2013 and 2016⁵

New-user rates fell from 1.26% in 2013 to 0.48% in 2016; established use fell 48% over the same period.

increase in incident TRT prescribing from 2002 to 2013 among men aged 40 to 65, followed by a decrease of more than 50% from 2013 to 2016⁶

Applies to men with and without depression or anxiety in a cohort of 5,565,649 insured men.

FDA required labeling changes stating testosterone is not approved for age-related low testosterone and warning of possible heart attack and stroke risk¹

Epic Research links the decline in prescribing after 2013 to this period of regulatory caution.

of male patients aged 50 to 64 had an active testosterone prescription in 2025, the highest of any age group¹

Above this group's prior peak of 1.30% in 2013.

of male patients aged 40 to 49 had an active testosterone prescription in 2025¹

of male patients aged 18 to 29 had an active testosterone prescription in 2025, the lowest of any age group¹

Rates in this group stayed between 0.10% and 0.15% throughout the study period.

of commercially insured men aged 60 to 69 used androgens in 2011, the highest rate of any age group that year⁴

increase in testosterone treatment prevalence among people aged 25 to 34 between 2018 and 2022²

Prevalence rose 45% among those aged 35 to 44 and 12% among those 65 and older. Data include all sexes.

increase in testosterone treatment prevalence among people aged 24 and under between 2018 and 2022²

The authors note females became the majority of patients in this age group by 2022, likely reflecting gender-affirming care.

of new androgen users had their testosterone level measured in the 12 months before starting treatment⁴

Commercially insured men aged 40 and older, 2001 to 2011.

of new androgen users had a hypogonadism diagnosis in the year before starting treatment⁴

Other common diagnoses were fatigue (34.49%), erectile dysfunction (31.88%) and psycho-sexual dysfunction (11.75%).

of men aged 40 to 65 did not have a testosterone lab test before starting TRT⁶

Insured men with and without depression or anxiety, 2002 to 2016.

US men who started testosterone in 2000 to 2011 were analyzed in a study that found many initiated without recent testing⁷

The authors also report that US men initiated treatment at normal testosterone levels more often than men in the United Kingdom.

was spent by Medicare Part D on generic testosterone cypionate injections in 2024⁸

Covering 1,118,253 claims. Figures are gross drug costs in the Part D Spending by Drug dataset.

Medicare Part D beneficiaries used generic testosterone cypionate in 2024, up from 195,172 in 2020⁸

was spent by Medicare Part D on generic testosterone (non-cypionate products such as gels) in 2024⁸

Listed under the generic name Testosterone, for 132,638 beneficiaries and 556,670 claims.

average Medicare Part D spending per dosage unit for Aveed (testosterone undecanoate injection) in 2024⁸

Versus $8.33 per dosage unit for generic testosterone cypionate, weighted averages.

was spent by Medicare Part D on Jatenzo (oral testosterone undecanoate) in 2024, for 1,758 beneficiaries⁸

direct-to-consumer testosterone platforms offered testosterone to a secret shopper whose levels were normal⁹

The scenario was a 34-year-old man with total testosterone of 675 ng/dL who wanted future fertility.

direct-to-consumer platforms asked about recent cardiovascular events or desire for future fertility⁹

In addition, 5 of 6 treating platforms did not discuss the risk of polycythemia.

Hims & Hers launched a low testosterone category with at-home blood testing and compounded enclomiphene¹⁰

The company said branded oral testosterone (KYZATREX) and injectable testosterone would follow in 2026.

DEA and HHS extended telemedicine flexibilities that let practitioners prescribe Schedule II to V medications by video without a prior in-person visit¹¹

Fourth temporary extension, covering January 1 to December 31, 2026. Testosterone is a Schedule III controlled substance.

of men had a major adverse cardiac event on testosterone gel versus placebo in the TRAVERSE trial¹²

5,246 men aged 45 to 80 with low testosterone and existing or high cardiovascular risk; hazard ratio 0.96, meeting noninferiority.

FDA told testosterone makers to remove Boxed Warning language on increased cardiovascular risk and add class-wide blood pressure warnings¹³

The Limitation of Use for age-related hypogonadism was retained.

members on an FDA expert panel that on December 10, 2025 urged removing testosterone's controlled-substance status and widening label eligibility¹⁴

News report; the panel's recommendations are not binding.